Following the recent Bio-IT conference, Iya Khalil and fellow keynote panelists weigh in on how AI is impacting real-world drug discovery efforts. Read the full article here.

The Healthcare Technology Report evaluates the hundreds of CEOs that lead exemplary organizations in the fields of medical devices, biotech, healthcare analytics, healthcare software and other related areas. They gather data on each nominee’s professional background...

"AI is being used to really leverage learning from large-scale datasets, and those large-scale datasets are used to get to better novel targets." - Iya Khalil, GNS Co-Founder and COO, joins Mike May of Genetic Engineering & Biotechnology News to discuss AI in drug...

GNS Co-Founder and COO Iya Khalil weighed in on the stand-off between Bayesians and frequentist. Read the full piece here.

GNS CEO and Co-Founder Colin Hill is shares his thoughts on the stat of AI and biopharma with Fortune reporter Tiernan Ray. Read the full article here.

GNS Co-Founder Iya Khalil joins 49 other female entrepreneurs who are pushing the frontiers of innovation across various industries. Read the full list here.

GNS Co-Founder and CEO Colin Hill sat down with Outsourcing Pharma's Melissa Fassbender to discuss how in silico are making personalized medicine a reality. The interview covered how technology is driving pharma efforts to transition from resource-intensive trials to...

GNS Co-Founder and CEO Colin Hill joined the ChasmPartners Roundtable to discuss the innovative approaches leveraging data and analytics being applied to drug development with Miki Kapoor, CEO of Verana Health, and Ken Tarkoff, CEO of Syapse. The conversation covered...

When Iya Khalil founded GNS Healthcare with Colin Hill in 2000, the AI and machine learning in healthcare field was in its infancy. As a pioneer in the space, Iya has helped steer and shape the growth of data-driven healthcare and precision medicine. For this work,...